Exhibit 10.5 


 


SECURITIES
PURCHASE AGREEMENT


 


THIS SECURITIES PURCHASE AGREEMENT
(this “Agreement”) is made effective as of 12:01 a.m. on September 29, 2021 (the “SPA
Effective Date”), by and among Amicus Therapeutics, Inc., a Delaware corporation with its principal place of business
at 3675 Market Street, Philadelphia, PA 19104 (“Amicus”), and each Purchaser identified on the signature pages hereto
(each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).


 


BACKGROUND


 


Amicus desires to sell to
each Purchaser and each Purchaser desires to purchase from Amicus such number of Shares (as defined below) set forth opposite such Purchaser’s
name on Schedule A attached hereto, at a price of $10.18 per Share (the “Per Share Price”) and on the
terms and subject to the conditions set forth in this Agreement (the “Offering”).


 


TERMS


 


NOW, THEREFORE, in consideration
of the foregoing recitals and the mutual covenants and agreements contained herein, the Parties hereto, intending to be legally bound,
do hereby agree as follows:


 


1.             Definitions.
The capitalized terms used herein shall have the meanings ascribed to them below or at such other place in this Agreement as is indicated
below:


 


1.1           “Affiliate”
means, with respect to any specified Person, at any time, a Person that, directly or indirectly, through one or more intermediaries, controls,
or is controlled by, or is under common control with, such specified Person at such time. For purposes of this definition, “control,”
when used with respect to any specified Person, shall mean (a) the direct or indirect ownership of more than 50% (or such lesser
percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the total voting power of
securities or other evidences of ownership interest in such Person or (b) the power to direct or cause the direction of the management
and policies of such Person, directly or indirectly, whether through ownership of voting securities, by contract or otherwise.


 


1.2           “Closing”
has the meaning ascribed to such term in Section 3.1.


 


1.3           “Common
Stock” means the common stock of Amicus, par value $0.01 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed into.


 


1.4           “Cut
Back Shares” has the meaning ascribed to such term in Section 6.1.


 


1.5           “Exchange
Act” means the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated thereunder.


 


1.6           “FDA”
has the meaning ascribed to such term in Section 4.7


 






    


     


    

 


1.7           “FDA
Documents” has the meaning ascribed to such term in Section 4.7.


 


1.8           “GAAP”
means generally accepted accounting principles in the United States.


 


1.9           “Holder”
means each Person owning of record Registrable Securities that have not been sold to the public.


 


1.10         “Indemnified
Party” has the meaning ascribed to such term in Section 6.5(c).


 


1.11         “Indemnifying
Party” has the meaning ascribed to such term in Section 6.5(c).


 


1.12         “Knowledge”
means the knowledge of such Person, assuming that such Person engaged in reasonable inquiry or investigation with respect to the relative
subject matter.


 


1.13         “Lock-Up
Period” has the meaning ascribed to such term in Section 7.1.


 


1.14         “Material
Adverse Effect” on or with respect to an entity (or group of entities taken as a whole) means any state of facts, event,
change or effect that has had, or that would reasonably expected to have, (i) a material adverse effect on the business, properties,
prospects, results of operations or financial condition of such entity (or of such group of entities taken as a whole) or (ii) a
material adverse effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby.


 


1.15         “Nasdaq”
means the Nasdaq Stock Market, Inc.


 


1.16         “Offering”
has the meaning ascribed to such term in the Background.


 


1.17         “Party”
means a party to this Agreement.


 


1.18         “Per
Share Price” has the meaning ascribed to such term in the Background.


 


1.19         “Person”
means any individual, firm, corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint
venture, joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind, and shall include
any successor (by merger or otherwise) of such entity.


 


1.20         “Press
Release” has the meaning ascribed to such term in Section 9.3.


 


1.21         “Purchase
Price” has the meaning ascribed to such term in Section 2.1.


 


1.22         “Purchaser
Indemnitee” has the meaning ascribed to such term in Section 6.5.


 


1.23         “Register,”
 “Registered,” and “Registration” refer to a registration effected by preparing and
filing a Registration Statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such Registration
Statement or document by the SEC.


 


1.24         “Registrable
Securities” means (a) the Shares and (b) any shares of Common Stock or other securities issued as (or issuable
upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect
to, or in exchange for or in replacement of, the Shares by way of stock dividend, stock split or in connection with a combination of shares,
recapitalization or other reorganization or otherwise. Notwithstanding the foregoing, as to any particular Shares or other securities
described above, once issued they shall cease to be Registrable Securities when (i) a registration statement with respect to the
sale of such securities shall have become effective under the Securities Act and such securities shall have been disposed of in accordance
with such registration statement, (ii) they shall have been distributed pursuant to Rule 144 (or any successor provision) under
the Securities Act, (iii) such securities may be sold without volume restrictions pursuant to Rule 144, as determined by the
counsel to Amicus pursuant to a written opinion letter to such effect, addressed and acceptable to Amicus’ transfer agent, or (iv) such
securities shall have been otherwise transferred in a private transaction in which the rights under Section 6 hereof have
not been assigned in connection with such transfer.


 






    -2-


     


    

 


1.25         “Registration
Period” has the meaning ascribed to such term in Section 6.3(a).


 


1.26         “Registration
Statement” means a registration statement filed pursuant to the Securities Act.


 


1.27         “Restriction
Termination Date” has the meaning ascribed to such term in Section 6.1.


 


1.28         “Rule 144”
means Rule 144 promulgated under the Securities Act, or any successor rule.


 


1.29         “Sanctions”
has the meaning ascribed to such term in Section 4.20.


 


1.30         “Sanctioned
Country” has the meaning ascribed to such term in Section 4.20.


 


1.31         “SEC”
means the U.S. Securities and Exchange Commission.


 


1.32         “SEC
Documents” has the meaning ascribed to such term in Section 4.7.


 


1.33         “SEC
Guidance” means (a) any publicly-available written guidance, or rule of general applicability of the SEC staff,
or (b) written comments, requirements or requests of the SEC staff to Amicus in connection with the review of a Registration Statement.


 


1.34         “SEC
Restrictions” has the meaning ascribed to such term in Section 6.1.


 


1.35         “Securities
Act” means the Securities Act of 1933, as amended, together with the rules and regulations promulgated thereunder.


 


1.36         “Purchase
Price” has the meaning ascribed to such term in Section 2.1.


 


1.37         “Shares”
means the shares of Common Stock to be issued to each Purchaser pursuant to this Agreement.


 


1.38         “Trading
Day” means a day on which the Common Stock is traded on Nasdaq.


 






    -3-


     


    

 


1.39         “Transaction
Documents” means this Agreement and any other documents or agreements executed in connection with the transactions contemplated
hereunder.


 


1.40         “Transfer
Agent” means American Stock Transfer & Trust Company, LLC, the company’s transfer agent and registrar for
Common Stock, and any successor appointed in such capacity.


 


2.             Purchase
and Sale.


 


2.1           On
terms and conditions as set forth herein, Amicus hereby issues and sells to the Purchasers, and the Purchasers hereby purchase from Amicus,
an aggregate of 7,858,546 Shares at the Per Share Price for an aggregate purchase price of $79,999,998.66 (the “Purchase Price”).


 


2.2           Schedule
A hereto sets forth the number of Shares to be purchased by each Purchaser and the portion of the Purchase Price to be paid by such
Purchaser for such Shares.


 


3.             Closing.


 


3.1           Closing.
The completion of the sale and purchase of the Shares (the “Closing”) shall occur upon the execution of this
Agreement.


 


3.2           Deliveries.
Subject to the terms and conditions hereof:


 


(a)            Each
Purchaser shall deliver to Amicus the Purchase Price attributable to the Shares purchased by such Purchaser by wire transfer of immediately
available funds to the following account:


 


	Bank:
	Bank Address:
	Beneficiary:
	Beneficiary Address:
	ABA:
	Account:
	SWIFT Code:


 


(b)            Upon
receipt of a Purchaser’s share of the Purchase Price, Amicus shall deliver to such Purchaser the applicable Shares to be registered
in book entry form in the name of such Purchaser on Amicus’s share register. Within one (1) business day of the date hereof,
Amicus will provide each Purchaser with written confirmation of the registration contemplated by Section 3(b)(i). Each of
the Parties shall also deliver such other documents as are required to be delivered by the Parties pursuant to the terms of this Agreement.


 






    -4-


     


    

 


4.             Representations
and Warranties of Amicus. Except as disclosed in Amicus’ disclosure schedules provided to the Purchasers along with this
Agreement, Amicus hereby represents and warrants to the Purchasers as of the SPA Effective Date (except as set forth below), as follows:


 


4.1           Capitalization.
As of September 27, 2021, the authorized capital stock of Amicus consisted of (a) 500,000,000 shares of Common Stock, of which
(i) 267,287,163 shares were issued and outstanding, and (ii) 40,298,907 shares have been reserved for issuance under Amicus’
Amended and Restated 2007 Equity Incentive Plan; and (b) 10,000,000 shares of preferred stock, none of which is issued and outstanding.
All issued and outstanding shares of Amicus’ capital stock have been duly authorized and validly issued, and are fully paid and
nonassessable, and were issued in compliance with all applicable federal and state securities laws. As of the SPA Effective Date, there
are no preemptive or similar rights on the part of any holder of any class or securities of Amicus. As of the SPA Effective Date, except
as set forth in the SEC Documents or as described or referred to above, there are no securities convertible into or exchangeable for,
or options, warrants, calls, subscriptions, rights, contracts, commitments, or understandings of any kind to which Amicus is a party or
by which it is bound obligating Amicus to issue, deliver or sell, or cause to be issued, delivered or sold additional shares of its capital
stock or other voting securities of Amicus. As of the SPA Effective Date, there are no outstanding agreements of Amicus to repurchase,
redeem or otherwise acquire any shares of its capital stock.


 


4.2           Litigation.
There are no actions, suits, proceedings or, to its Knowledge, any investigations, pending or currently threatened against Amicus that
questions the validity of this Agreement or the issuance of the Common Stock contemplated hereby, nor to its Knowledge, is there any basis
therefor. As of the SPA Effective Date, there is no other material action, suit, or proceeding pending or, to the Knowledge of Amicus,
currently threatened against Amicus. As of the SPA Effective Date, there are no material outstanding consents, orders, decrees or judgments
of any governmental entity naming Amicus.


 


4.3           Organization
and Good Standing. Amicus is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware
and has all requisite corporate power and authority to own, lease and operate its properties and carry on its business as now conducted.
Amicus is duly qualified and is in good standing as a foreign corporation in each jurisdiction in which the properties owned, leased or
operated, or the business conducted, by it requires such qualification except where the failure to be so qualified or in good standing,
individually or in the aggregate, would not have a Material Adverse Effect.


 


4.4           Authorization.
All corporate actions on the part of Amicus, its officers, directors and stockholders necessary for the authorization, execution and delivery
of each of the Transaction Documents and for the issuance of the Shares have been taken. Amicus has the requisite corporate power to enter
into each of the Transaction Documents and to carry out and perform its obligations thereunder. Each of the Transaction Documents have
been duly authorized, executed and delivered by Amicus and, upon due execution and delivery by the Purchasers, each of the Transaction
Documents will be a valid and binding agreement of Amicus, except as enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors’ rights generally or by equitable principles.


 


4.5           Subsidiaries.
Except as set forth in the disclosure schedules to this Agreement, Amicus does not currently own or control, directly or indirectly, any
interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity.
Amicus is not a participant in any joint venture, partnership or similar arrangement other than as has been disclosed in SEC Documents.


 






    -5-


     


    

 


4.6           No
Conflict With Other Instruments. Neither the execution, delivery nor performance of any of the Transaction Documents, nor the consummation
by Amicus of the transactions contemplated hereby will result in any violation of, be in conflict with, cause any acceleration or any
increased payments under, or constitute a default under, with or without the passage of time or the giving of notice: (a) any provision
of Amicus’ certificate of incorporation or bylaws as in effect at the Closing; (b) any provision of any law, regulation, judgment,
decree or order to which Amicus is a party or by which it or any of its assets is bound, (c) any note, mortgage, contract, agreement,
license, waiver, exemption, order or permit.


 


4.7           Disclosure
Documents.


 


(a)            For
the two years preceding the SPA Effective Date, Amicus has filed, on a timely basis or has received a valid extension as of such time
of filing and has thereafter made such filings prior to the expiration of any such extensions, all reports, schedules, forms, statements
and other documents required to be filed by Amicus with the SEC under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or
15(d) thereof, (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
referred to herein as the “SEC Documents”) and with the U.S. Food and Drug Administration (“FDA”)
under its applicable regulations (“FDA Documents”), and Amicus has paid all fees and assessments due and payable
in connection with the SEC Documents and the FDA Documents. As of their respective dates, the SEC Documents and the FDA Documents complied
in all material respects with all statutes and applicable rules and regulations of the SEC or FDA, as applicable, including the requirements
of the Securities Act or the Exchange Act, as applicable, and none of the SEC Documents or FDA Documents, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.


 


(b)            The
audited financial statements of Amicus included in Amicus’ SEC Documents comply in all material respects with the published rules and
regulations of the SEC with respect thereto, and such audited financial statements (i) were prepared from the books and records of
Amicus, (ii) were prepared in accordance with GAAP applied on a consistent basis (except as may be indicated therein or in the notes
or schedules thereto) and (iii) present fairly the financial position of Amicus as of the dates thereof and the results of operations
and cash flows for the periods then ended. The unaudited financial statements included in the SEC Documents comply in all material respects
with the published rules and regulations of the SEC with respect thereto, and such unaudited financial statements (i) were prepared
from the books and records of Amicus, (ii) were prepared in accordance with GAAP, except as otherwise permitted under the Exchange
Act and the rules and regulations thereunder, applied on a consistent basis (except as may be indicated therein or in the notes or
schedules thereto) and (iii) present fairly the financial position of Amicus as of the dates thereof and the results of operations
and cash flows (or changes in financial condition) for the periods then ended, subject to normal year-end adjustments and any other adjustments
described therein or in the notes or schedules thereto. The interactive data in eXtensible Business Reporting Language included in the
SEC Documents fairly presents the information called for in all material respects and has been prepared in all material respects in accordance
with the SEC’s rules and guidelines applicable thereto.


 






    -6-


     


    

 


4.8           Absence
of Certain Events and Changes. Since the date of Amicus’ Quarterly Report on Form 10-Q for the quarter ended on June 30,
2021: (a) Amicus has conducted its business in the ordinary course consistent with past practice, (b) there has not been any
event, change or development which, individually or in the aggregate, would have a Material Adverse Effect, taken as a whole, (c) Amicus
has not incurred any material liabilities (contingent or otherwise) other than expenses incurred in the ordinary course of business consistent
with past practice, (d) Amicus has not altered its method of accounting in any material respect, and (e) Amicus has not declared
or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase
or redeem any shares of its capital stock.


 


4.9           Intellectual
Property. Amicus owns, or has an exclusive right pursuant to a valid, written license agreement to use and exploit, all material intellectual
property used in or necessary for the conduct of the business of Amicus as conducted as of the Closing and the conduct of its business
will not conflict in any material respect with any such rights of others. No claims have been asserted by a third party in writing (a) alleging
that the conduct of the business of Amicus has infringed or misappropriated any intellectual property rights of such third party, or (b) challenging
or questioning the validity or effectiveness of any intellectual property right of Amicus, and, to the Knowledge of Amicus, there is no
valid basis for any such claim (a) or (b). To the Knowledge of Amicus, no third party is misappropriating or infringing any intellectual
property right of Amicus. No loss or expiration of any of Amicus’ material intellectual property is pending, or, to the Knowledge
of Amicus, threatened. Amicus has taken reasonable steps in accordance with standard industry practices to protect its rights in its Intellectual
Property and at all times has maintained the confidentiality of all information used in connection with the business that constitutes
or constituted a trade secret of Amicus.


 


4.10         Compliance
with Applicable Law. Amicus has all material permits, licenses, franchises, authorizations, orders and approvals of, and has made
all filings, applications and registrations with, governmental entities that are required in order to permit Amicus to own or lease properties
and assets and to carry on its business as presently conducted that are material to Amicus. Amicus has complied and is in compliance in
all material respects with all statutes, laws, regulations, rules, judgments, orders and decrees of all governmental entities applicable
to it that relate to its business. Except as set forth in the disclosure schedules to this Agreement, Amicus has not received any notice
alleging noncompliance, and, to the Knowledge of Amicus, Amicus is not under investigation with respect to, or threatened to be charged,
with any material violation of any applicable statutes, laws, regulations, rules, judgments, orders or decrees of any governmental entities.


 


4.11         Valid
Issuance of Shares. When issued, sold and delivered in accordance with the terms hereof for the consideration expressed herein, the
Shares will be duly and validly authorized and issued, fully paid and non-assessable, free and clear of all liens, and, based in part
on the representations of the Purchasers in Section 5 of this Agreement, will be issued in compliance with all applicable
federal and state securities laws.


 


4.12         Governmental
Consents. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with,
any federal, state or local governmental authority on the part of Amicus is required in connection with the consummation of the transactions
contemplated by the Transaction Documents, except for notices required or permitted to be filed with certain state and federal securities
commissions, which notices will be filed on a timely basis.


 






    -7-


     


    

 


4.13         No
Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection
with the transactions contemplated by the Transaction Documents based on arrangements made by Amicus.


 


4.14         No
Undisclosed Liabilities. Amicus does not have any liabilities (contingent or otherwise), except for (a) liabilities reflected
or reserved against in financial statements of Amicus included in the SEC Documents filed with the SEC prior to the date of each of the
Transaction Documents, and (b) liabilities that have not been and would not reasonably be expected to be material.


 


4.15         Internal
Controls. Amicus maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions
are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability, and (iii) access
to assets or incurrence of liabilities is permitted only in accordance with management’s general or specific authorization. Since
the end of Amicus’s most recent audited fiscal year, to its Knowledge, there have been no significant deficiencies or material weakness
detected in Amicus’s internal control over financial reporting (whether or not remediated) and no change in Amicus’s internal
control over financial reporting that has materially affected, or is reasonably likely to materially affect, Amicus’s internal control
over financial reporting. Amicus is not aware of any change in its internal controls over financial reporting that has occurred during
its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Amicus’s internal control
over financial reporting.


 


4.16         Disclosure
Controls. Amicus and its subsidiaries maintain an effective system of “disclosure controls and procedures” (as defined
in Rule 13a-15(e) of the Exchange Act) that complies in all material respects with the requirements of the Exchange Act and
that has been designed to ensure that information required to be disclosed by Amicus in reports that it files or submits under the Exchange
Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, including
controls and procedures designed to ensure that such information is accumulated and communicated to Amicus’s management as appropriate
to allow timely decisions regarding required disclosure.


 


4.17         Compliance.
Amicus is not (i) in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse
of time or both, would result in a default by Amicus under), nor has Amicus received notice of a claim that it is in default under or
that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by
which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) in violation of any judgment,
decree or order of any court, arbitrator or governmental body or (iii) in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to environmental protection,
occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or
reasonably be expected to result in a Material Adverse Effect.


 






    -8-


     


    

 


4.18         No
Unlawful Payments. Neither Amicus nor any of its subsidiaries nor, to the knowledge of Amicus, any director, officer, employee, agent,
affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i) used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken
an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic
government official or employee, including of any government-owned or controlled entity or of a public international organization, or
any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate
for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended,
or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or
anti-corruption law; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful
benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit.
Amicus and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed
to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.


 


4.19         Compliance
with Anti-Money Laundering Laws. The operations of Amicus and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts
business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or
enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”) and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries
with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.


 


4.20         No
Conflicts with Sanctions Laws. Neither Amicus nor any of its subsidiaries nor, to the knowledge of Amicus, any director, officer,
employee, agent, affiliate or other person associated with or acting on behalf of Amicus or any of its subsidiaries is currently the subject
or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign
Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation
as a “specially designated national” or “blocked person”), the United Nations Security Council the European Union,
Her Majesty’s Treasury or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company,
any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including,
without limitation, Crimea, Cuba, Iran, North Korea and Syria (each, a “Sanctioned Country”); and Amicus
will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business
with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate
any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person
(including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the
past five years, Amicus and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions
with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country.


 






    -9-


     


    

 


4.21         Investment
Company. Amicus is not required to be registered as, and immediately following the Closing will not be required to register as, an
 “investment company” within the meaning of the Investment Company Act of 1940, as amended.


 


4.22         Bad
Actor Disqualification. None of Amicus, any predecessor or affiliated issuer of Amicus nor, to Amicus’s Knowledge, any director
or executive officer of Amicus or any promoter connected with Amicus in any capacity, is subject to any of the “bad actor”
disqualifications within the meaning of Rule 506(d) under the Securities Act, except for a disqualification event covered by
Rule 506(d)(2) or (d)(3).


 


4.23         Investment
Matters. Assuming the accuracy of each Purchaser’s representations and warranties set forth in Section 5, no registration
under the Securities Act is required for the offer and sale of the Shares to the Purchasers hereunder. The Shares (i) were not offered
to the Purchasers by any form of general solicitation or general advertising and (ii) are not being offered to the Purchasers in
a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws.


 


5.             Representations
And Warranties Of Purchasers. Each Purchaser hereby represents and warrants to Amicus as of the SPA Effective Date as follows:


 


5.1           Legal
Power. Purchaser has the requisite corporate power to enter into each of the Transaction Documents, and to carry out and perform its
obligations under the terms of the Transaction Documents.


 


5.2           Due
Execution. Each of the Transaction Documents have been duly authorized, executed and delivered by Purchaser, and, upon due execution
and delivery by Amicus, each of the Transaction Documents will be a valid and binding agreement of Purchaser, except as enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or by
equitable principles.


 


5.3           Investment
Representations. In connection with the offer, purchase and sale of the Shares Purchaser makes the following representations:


 


(a)            Purchaser
is acquiring the Shares for its own account, not as nominee or agent, for investment and not with a view to, or for resale in connection
with, any distribution or public offering thereof within the meaning of the Securities Act.


 






    -10-


     


    

 


(b)            Purchaser
understands that:


 


(i)            The
Shares have not been registered under the Securities Act by reason of a specific exemption therefrom, that such securities may be required
to be held by it indefinitely under applicable securities laws, and that each Purchaser must, therefore, bear the economic risk of such
investment indefinitely, unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration.


 


(ii)           Each
book entry position representing Shares will be endorsed with the following legend:


 


THE SECURITIES REPRESENTED HEREBY HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES.
THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED
UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM OR UNLESS THE COMPANY HAS RECEIVED
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.


 


; and


 


(iii)          Amicus
will instruct its transfer agent not to register the transfer of the Shares or any portion thereof, unless the conditions specified in
the foregoing legend are satisfied.


 


(c)            Each
Purchaser has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of
the investment in the Shares to be purchased hereunder.


 


(d)            Each
Purchaser acknowledges and agrees that the Purchaser is purchasing the Shares from Amicus. Each Purchaser further acknowledges that there
have been no representations, warranties, covenants and agreements made to the Purchaser by or on behalf of Amicus or any of its respective
affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing or any
other person or entity, expressly or by implication, other than those representations, warranties, covenants and agreements of Amicus
expressly set forth in this Agreement.


 


(e)            Each
Purchaser is an “accredited investor” as such term is defined in Rule 501(a) of the rules and regulations promulgated
under the Securities Act. Each Purchaser acknowledges that it is aware that there are substantial risks incident to the purchase and ownership
of the Shares, including, without limitation, those set forth in the SEC Documents.


 


(f)             Each
Purchaser became aware of this offering of the Shares solely by means of direct contact between the Purchaser and Amicus or a representative
of Amicus, and the Shares were offered to the Purchaser solely by direct contact between the Purchaser and the Amicus or a representative
of Amicus. The Purchaser did not become aware of this offering of the Shares, nor were the Shares offered to the Purchaser, by any other
means.


 






    -11-


     


    

 


6.             Registration
Rights.


 


6.1           Registration.
As soon as reasonably practicable, but no event later than 50 days after the Closing, Amicus shall prepare and file with the SEC a Registration
Statement covering the resale of all, or such portion as permitted by SEC Guidance (provided that, Amicus shall use commercially reasonable
efforts to advocate with the SEC for the registration of the maximum number of the Registrable Securities permitted by SEC Guidance),
of the Registrable Securities and use commercially reasonable efforts to cause a Registration Statement to be declared effective (including,
without limitation, the execution of any required undertaking to file post-effective amendments) as promptly as possible after the filing
thereof, but in no event later than ten (10) business days after the SEC has notified that Amicus that it will not review, or has
completed its review, of the Registration Statement. The Registration Statement shall be on Form S-3 (except if Amicus fails to meet
one or more of the registrant requirements specified in General Instruction I.A. on Form S-3, such registration shall be on another
appropriate form in accordance herewith). In the event that, despite Amicus’s commercially reasonable efforts and compliance with
the terms of this Section 6.1, the SEC refuses to alter its position, the Company shall (i) remove from the Registration
Statement such portion of the Registrable Securities (the “Cut Back Shares”) and/or (ii) agree to such
restrictions and limitations on the registration and resale of the Registrable Securities as the staff of the SEC may require to assure
Amicus’s compliance with the requirements of Rule 415 (collectively, the “SEC Restrictions”); provided,
however, that Amicus shall not agree to name any Purchaser as an “underwriter” in such Registration Statement without the
prior written consent of such Purchaser. Any cutback imposed on the Purchasers pursuant to this Section 6.1 shall be allocated
among the Purchasers on a pro rata basis, unless the SEC Restrictions otherwise require or provide or the Purchasers holding a majority
of the Registrable Shares otherwise agree. From and after the such date as the Company is able to effect the registration of such Cut
Back Shares in accordance with any SEC Restrictions (such date, the “Restriction Termination Date” of such Cut
Back Shares) applicable to any Cut Back Shares, all of the provisions of this Section 6 shall again be applicable to such
Cut Back Shares; provided, however, that (x) the Filing Deadline for the Registration Statement including such Cut Back Shares shall
be 10 business days after such Restriction Termination Date.


 


6.2           Expenses
Of Registration. Amicus shall pay all fees and expenses incurred in connection with any registration, qualification, exemption or
compliance by Amicus in the performance of its obligations pursuant to this Section 6, whether or not any Registrable Securities
are sold pursuant to a Registration Statement, and including all registration and filing fees, exchange listing fees, and the fees and
expenses of counsel and accountants for Amicus.


 






    -12-


     


    

 



 


6.3           Obligations
Of Amicus. In the case of registration, qualification, exemption or compliance effected by Amicus pursuant to the Transaction Documents,
Amicus will, upon request of any Purchaser, inform such Purchaser as to the status of such registration, qualification, exemption and
compliance. Amicus shall, at its expense and in addition to its obligations under Section 6.1, as expeditiously as reasonably
possible:


 


(a)            use
its commercially reasonable efforts to keep such registration, and any required qualification, exemption or compliance under state securities
laws, continuously effective with respect to the Purchasers and its permitted assignees, until the date all Shares registered by such
Registration Statement shall have been sold or may be sold pursuant to Rule 144 without regard to volume limitations. The period
of time during which Amicus is required hereunder to keep the Registration Statement effective is referred to herein as the “Registration
Period.”


 


(b)           advise
Purchasers promptly (and, in any event, within five business days):


 


(i)            when
the Registration Statement or any amendment thereto has been filed with the SEC and when the Registration Statement or any post-effective
amendment thereto has become effective;


 


(ii)           of
the receipt by Amicus of any notification from the SEC of any stop order suspending the effectiveness of the Registration Statement or
the initiation of any proceedings for such purpose;


 


(iii)          of
the receipt by Amicus of any notification with respect to the suspension of the qualification of the Registrable Securities included therein
for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and


 


(iv)          of
the occurrence of any event that requires the making of any changes in the Registration Statement or the prospectus so that, as of such
date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to
make the statements therein (in the case of the prospectus, in the light of the circumstances under which they were made) not misleading;


 


(c)            use
its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement as
soon as reasonably practicable;


 


(d)           if
any Purchaser so requests in writing, promptly furnish to such Purchaser, without charge, at least one copy of such Registration Statement
and any post-effective amendment thereto, including financial statements and schedules, and, if explicitly requested, all exhibits in
the form filed with the SEC;


 


(e)            during
the Registration Period, promptly deliver to each Purchaser, without charge, at least one copy of the prospectus included in such Registration
Statement and any amendment or supplement thereto and as many additional copies as each Purchaser may reasonably request; and Amicus consents
to the use, consistent with the provisions hereof, of the prospectus or any amendment or supplement thereto by each Purchaser in connection
with the offering and sale of the Registrable Securities covered by the prospectus or any amendment or supplement thereto;


 


(f)             during
the Registration Period, if a Purchaser so requests in writing, deliver to such Purchaser, without charge, (i) one copy of the following
documents, other than those documents available via EDGAR (and excluding, in each case, exhibits thereto): (A) its annual report
to its stockholders, if any (which annual report will contain financial statements audited in accordance with GAAP by a firm of certified
public accountants of recognized standing), (B) if not included in substance in its annual report to stockholders, its annual report
on Form 10-K (or similar form), (C) its definitive proxy statement with respect to its annual meeting of stockholders, (D) each
of its quarterly reports to its stockholders, and, if not included in substance in its quarterly reports to stockholders, its quarterly
report on Form 10-Q (or similar form), and (E) a copy of the Registration Statement; and (ii) if explicitly requested,
any exhibits filed with respect to the foregoing;


 






    -13-


     


    

 


(g)            upon
the occurrence of any event contemplated by Section 6.3(b)(iv), Amicus will use its commercially reasonable efforts to as
soon as reasonably practicable prepare a post-effective amendment to the Registration Statement or a supplement to the related prospectus,
or file any other required document so that, as thereafter delivered to the Purchasers, the prospectus will not include any untrue statement
of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading;


 


(h)            comply
in all material respects with all applicable rules and regulations of the SEC which could affect the sale of the Registrable Securities;


 


(i)             use
its commercially reasonable efforts to cause all Registrable Securities to be listed on each securities exchange or market, if any, on
which equity securities issued by Amicus have been listed;


 


(j)             use
its commercially reasonable efforts to take all other steps necessary to effect the registration of the Registrable Securities contemplated
hereby and to enable the Purchasers to sell Registrable Securities under Rule 144; and


 


(k)            permit
counsel for the Purchasers to review the Registration Statement and all amendments and supplements thereto, within two business days prior
to the filing thereof with the SEC;


 


provided
that, in the case of clause (k) above, Amicus will not be required to delay the filing of the Registration Statement or any amendment
or supplement thereto to incorporate any comments to the Registration Statement or any amendment or supplement thereto by or on behalf
of any Purchaser if such comments would require a delay in the filing of such Registration Statement, amendment or supplement, as the
case may be.


 


6.4           Furnishing
Information.


 


It shall be a condition precedent
to the obligations of Amicus to take any action pursuant to Section 6.1 that each of the selling Holders shall furnish to
Amicus such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities
as shall be legally required under the Securities Act or otherwise required by the SEC to effect the registration of their Registrable
Securities.


 






    -14-


     


    

 


6.5           Indemnification;
Contribution.


 


(a)           Amicus
shall indemnify and hold harmless each Holder (including the employees, agents, representatives, officers and directors of each Purchaser
and its Affiliates) (each a “Purchaser Indemnitee”) from and against any and all losses, claims, damages, liabilities
and expenses (including reasonable costs of investigation) arising out of or based upon any untrue, or allegedly untrue, statement of
a material fact contained in any Registration Statement, prospectus or preliminary prospectus or notification or offering circular prepared
by Amicus in connection with the registration and/or offering of the Registrable Securities (as amended or supplemented if Amicus shall
have furnished any amendments or supplements thereto) or arising out of or based upon any omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as the same are
caused by or contained in any information concerning such Holder furnished in writing to Amicus by such Holder specifically and expressly
for inclusion in such document.


 


(b)            Each
Holder shall indemnify and hold harmless Amicus, and its respective directors, officers, employees and each Person who controls Amicus
(within the meaning of the Securities Act and the Exchange Act) from and against any and all losses, claims, damages, liabilities and
expenses (including reasonable costs of investigation) arising out of or based upon any untrue, or allegedly untrue, statement of a material
fact contained in any Registration Statement, prospectus or preliminary prospectus or notification or offering circular prepared by Amicus
in connection with the registration and/or offering of the Registrable Securities (as amended or supplemented if Amicus shall have furnished
any amendments or supplements thereto) or arising out of or based upon any omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, if such statement or omission was made in reliance
upon and in conformity with any information concerning such Holder furnished in writing to Amicus by such Holder specifically and expressly
for use in the preparation of such document; provided, however, that in no event shall any indemnity under this Section 6.5(b) be
greater in amount than the aggregate dollar amount of the proceeds received by all of the Purchasers upon the sale of such Registrable
Securities.


 


(c)            Each
Person entitled to indemnification hereunder (the “Indemnified Party”) agrees to give prompt written notice
to the indemnifying party (the “Indemnifying Party”) after the receipt by the Indemnified Party of any written
notice of the commencement of any action, suit, proceeding or investigation or threat thereof made in writing for which the Indemnified
Party intends to claim indemnification or contribution pursuant to the Transaction Documents; provided, however, that the failure
to so notify the Indemnifying Party shall not relieve the Indemnifying Party of any liability that it may have to the Indemnified Party
hereunder unless, and only to the extent that, such failure results in the Indemnifying Party’s forfeiture of substantive rights
or defenses. If notice of commencement of any such action is given to the Indemnifying Party as above provided, the Indemnifying Party
shall be entitled to participate in and, to the extent it may wish, jointly with any other Indemnifying Party similarly notified, to assume
the defense of such action at its own expense, with counsel chosen by it and reasonably satisfactory to such Indemnified Party. The Indemnified
Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses
of such counsel (other than reasonable costs of investigation) shall be paid by the Indemnified Party unless (i) the Indemnifying
Party agrees to pay the same, (ii) the Indemnifying Party fails to assume the defense of such action with counsel reasonably satisfactory
to the Indemnified Party in its reasonable judgment or (iii) the named parties to any such action (including any impleaded parties)
have been advised by such counsel that either (x) representation of such Indemnified Party and the Indemnifying Party by the same
counsel would be inappropriate under applicable standards of professional conduct or (y) there may be one or more legal defenses
available to it which are different from or additional to those available to the Indemnifying Party. In either of such cases, the Indemnifying
Party shall not have the right to assume the defense of such action on behalf of such Indemnified Party. No Indemnifying Party shall be
liable for any settlement entered into without its written consent (other than in the case where the Indemnifying Party is unconditionally
released from liability and its rights are not adversely effected), which consent shall not be unreasonably withheld.


 






    -15-


     


    

 


(d)            If
the indemnification provided for in this Section 6.5 from the Indemnifying Party pursuant to applicable law is unavailable
to an Indemnified Party hereunder in respect of any losses, claims, damages, liabilities or expenses referred to therein, then the Indemnifying
Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result
of such losses, claims, damages, liabilities or expenses in such proportion as is appropriate to reflect the relative fault of the Indemnifying
Party and Indemnified Party in connection with the actions which resulted in such losses, claims, damages, liabilities or expenses, as
well as any other relevant equitable considerations. The relative faults of such Indemnifying Party and Indemnified Party shall be determined
by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact
or omission or alleged omission to state a material fact, has been made by, or relates to information supplied by, such Indemnifying Party
or Indemnified Party, and the parties’ relative intent, Knowledge, access to information and opportunity to correct or prevent such
action. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall
be deemed to include, subject to the limitations set forth in Sections 6.5(a), (b) and (c), any legal or other
fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree
that it would not be just and equitable if contribution pursuant to this Section 6.5(d) were determined by pro rata allocation
or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding
paragraph. No Person guilty of an intentional or fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution from any Person.


 


6.6           Rule 144
Reporting. In order to make the benefits of the rules and regulations of the SEC that may permit the sale of the Registrable
Securities to the public without registration available to the Holders, Amicus agrees to use commercially reasonable efforts to:


 


(a)            make
and keep public information available, as those terms are understood and defined in Rule 144(c)(1) or any similar or analogous
rule promulgated under the Securities Act, at all times after the SPA Effective Date;


 


(b)            file
with the SEC, in a timely manner, all reports and other documents required of Amicus under the Exchange Act; and


 






    -16-


     


    

 


(c)            so
long as any Holder owns any Registrable Securities, furnish such Holders forthwith upon request: (i) a written statement by Amicus
as to its compliance with the reporting requirements of Rule 144 under the Securities Act, and of the Exchange Act; (ii) a copy
of the most recent annual or quarterly report of Amicus; and (iii) such other reports and documents as a Holder may reasonably request
in availing itself of any rule of regulation of the SEC allowing it to sell any such securities without registration.


 


6.7           Assignment
of Registration Rights. The rights and obligations under this Section 6 may only be assigned by a Holder to a transferee
or assignee of Registrable Securities that is (a) an Affiliate or (b) a successor (by operation of law or otherwise) to substantially
all the business or assets of such Holder; provided, however, that such attempted assignment shall be void unless (i) such
Holder, within 30 days after such transfer, furnishes to Amicus written notice of the name and address of such transferee or assignee
and the securities with respect to which such registration rights are being assigned, and (ii) such transferee agrees to be subject
to all obligations and restrictions with respect to the Registrable Securities set forth in this Agreement.


 


7.             Stock
Ownership Governance.


 


7.1           Lock-Up
Period. Excluding any transfers or intra-company disposal of the Shares between a Purchaser and any of its Affiliates, for a period
of sixty (60) days following the SPA Effective Date (the “Lock-Up Period”), each Purchaser shall not, and shall
cause any other Holder not to, without the prior written consent of Amicus, sell, contract to sell, pledge or otherwise dispose of, directly
or indirectly, any Shares or enter into a transaction which would have the same effect. For the avoidance of doubt, this Section 7.1
shall only apply to Shares purchased pursuant to this Agreement and shall not impose any restrictions on any other securities of Amicus
owned by the Purchaser.


 


7.2           Remedies.
Without prejudice to the rights and remedies otherwise available to the parties, Amicus shall be entitled to equitable relief by way of
injunction if any Purchaser or any other Holder breaches or threatens to breach any of the provisions of this Section 7.


 


8.             Covenants.


 


8.1           Covenant
of Amicus.


 


(a)            Amicus
hereby covenants and agrees that it shall take all necessary and appropriate actions to ensure that it shall have available under its
certificate of incorporation as in effect at the Closing sufficient authorized but unissued shares of its Common Stock to issue and sell
to Purchasers all of the Shares.


 


(b)           From
the date hereof until such time as the Shares have been sold pursuant to Rule 144 or are eligible for resale under Rule 144(b)(1) or
any successor provision, Amicus will use commercially reasonable efforts to continue the listing and trading of its Common Stock on Nasdaq
and, in accordance, therewith, will use commercially reasonable efforts to comply in all respects with Amicus’s reporting, filing
and other obligations under the bylaws or rules of such market or exchange, as applicable.


 






    -17-


     


    

 


(c)            Amicus
shall not, and shall use its commercially reasonable efforts to ensure that no controlled Affiliate of Amicus shall, sell, offer for sale
or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will
be integrated with the offer or sale of the Shares in a manner that would require the registration under the Securities Act of the sale
of the Shares to the Investors. Amicus shall not take any action or steps that would adversely affect reliance by Amicus in any material
respect on Section 4(a)(2) for the exemption from registration for the transactions contemplated hereby or require registration
of the Shares under the Securities Act.


 


8.2           Removal
of Legends. In connection with any sale or disposition of the Shares by a Purchaser pursuant to Rule 144 or pursuant to any other
exemption under the Securities Act such that the Purchaser acquires freely tradable shares and upon compliance by the Purchaser with the
requirements of this Agreement, if requested in writing by the Purchaser, Amicus shall use its commercially reasonable efforts to request
that the transfer agent for the Common Stock (the “Transfer Agent”) remove any restrictive legends related to
the book entry account holding such Shares and make a new, unlegended entry for such book entry Shares sold or disposed of without restrictive
legends within two (2) Trading Days of receipt of such request from the Purchaser. Upon the earliest of such time as the Shares (i) have
been registered for resale pursuant to an effective registration statement, (ii) have been sold pursuant to Rule 144 or (iii) are
eligible for resale under Rule 144(b)(1) or any successor provision, Amicus shall (A) deliver to the Transfer Agent irrevocable
instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Shares, and (B) cause its counsel to
deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected
under the Securities Act. Amicus shall be responsible for the fees of its Transfer Agent and all DTC fees associated with such issuance.


 


9.             Miscellaneous.


 


9.1           Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts
of law thereof. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
Party at the address in effect for notices to it under the Transaction Documents and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law.


 


9.2           Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by the Parties and delivered to the other Parties, it being understood that
the Parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a “.pdf”
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such “.pdf” signature page were an original thereof.


 






    -18-


     


    

 


9.3           Public
Statements. Amicus shall no later than the close of business on the date immediately following the date hereof, either issue a press
release or file a Current Report on Form 8-K disclosing the material terms of the transactions contemplated hereby and any other
material, nonpublic information that Amicus may have provided to any Purchaser at any time prior thereto promptly following the execution
and delivery hereof, which shall have been previously reviewed by counsel for the Purchasers (the “Press Release”).
Amicus shall not include the name of any Purchaser in the Press Release or any other public announcement without the prior written consent
of such Purchaser. Subject to the foregoing, any statement to the public regarding this the Transaction Documents shall be approved in
advance by Amicus and the Purchasers, except as otherwise required by law, rule, regulation, legal process or applicable SEC Guidance.


 


9.4           Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties and their successors and permitted assigns.
Amicus may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Purchasers purchasing
at least 85% of the Shares issuable hereunder. Subject to Section 6.7, any Purchaser may assign any or all of its rights under
this Agreement to any Person to whom such Purchaser assigns or transfers any Shares, provided such transferee agrees in writing to be
bound, with respect to the transferred Shares, by the provisions of the Transaction Documents that apply to the “Purchasers.”


 


9.5           Entire
Agreement. The Transaction Documents, together with the exhibits and schedules hereto, contain the entire understanding of the Parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters (other than confidentiality agreements to which Amicus is a party to with the Purchasers), which the Parties acknowledge
have been merged into such documents, exhibits and schedules.


 


9.6           Separability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the Parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the Parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.


 


9.7           Rescission
and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of
the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
Amicus does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw,
in its sole discretion from time to time upon written notice to Amicus, any relevant notice, demand or election in whole or in part without
prejudice to its future actions and rights.


 


9.8           Replacement
of Shares. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, Amicus shall issue or cause
to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to Amicus of such loss, theft or
destruction. The applicant for a new certificate or instrument under such circumstances may also be required to pay a customary bond and
any reasonable third-party costs associated with the issuance of such replacement Shares.


 






    -19-


     


    

 


9.9           Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and Amicus will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be
adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agrees
to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.


 


9.10         Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto, shall be deemed to constitute the Purchasers as a partnership, an association, a
joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights, including without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in their review and negotiation of the Transaction Documents.


 


9.11         Amendment
and Waiver. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment,
by Amicus and Purchasers purchasing at least 85% of the Shares issuable hereunder or, in the case of a waiver, by the Party against whom
enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right.


 


9.12         Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via email
at the email address set forth on the signature pages attached hereto prior to 5:30 p.m. (New York City time) on a Trading Day,
(b) the next Trading Day after the date of transmission, if such notice or communication is delivered via email at the email address
set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time)
on any Trading Day, (c) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier
service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages attached hereto.


 






    -20-


     


    

 


9.13         Fees
and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each Party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. Amicus shall pay all transfer agent fees, stamp taxes and other taxes
and duties levied in connection with the delivery of any Shares to the Purchasers.


 


9.14         Titles
and Subtitles. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.


 


9.15         Counterparts;
Effectiveness. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of
which together shall constitute one instrument. This Agreement shall become effective when each Party hereto shall have received counterparts
thereof signed and delivered (by telecopy or other electronic means) by the other Parties hereto. Counterparts may be delivered via facsimile,
electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act,
the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.


 


9.16         Construction.
The Parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.


 


9.17         No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the Parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
Section 6.5.


 






    -21-


     


    

 


This Securities Purchase Agreement is hereby executed
as of the date first above written.


 


	 	AMICUS:
	 	 
	 	Amicus Therapeutics, Inc.
	 	 
	 	By:	 /s/ Daphne Quimi
	 	 	Name:	Daphne Quimi
	 	 	Title:	Chief Financial Officer
	 	 
	 	Address:	3675 Market Street
	 	 	Philadelphia, PA 19104
	 	Email:	gcoffice@amicusrx.com





 


[Signature
Page to Securities Purchase Agreement]


 






    


     


    

 


	 	PURCHASER:
	 	 
	 	Avoro Life Sciences Fund LLC
	 	 
	 	By:	 /s/ Scott Epstein
	 	 	Name:	Scott
Epstein
	 	 	Title:	Partner, CFO &COO
	 	 	 	 
	 	Address:	110 Greene Street, Suite 800
	 	 	New York, New York 10012


 


[Signature
Page to Securities Purchase Agreement]


 






    


     


    

 


	 	PURCHASER:
	 	 
	 	Invus Public Equities, L.P.
	 	 
	 	By:	/s/
Khalil Barrage
	 	 	Name:	Khalil
Barrage
	 	 	Title:	Vice President of the General Partner
	 	 	 	 
	 	Address:	750 Lexington Ave, 30th FL
	 	 	New York, NY 10022


 


[Signature
Page to Securities Purchase Agreement]


 






    


     


    

 


	 	PURCHASER:
	 	 
	 	
    JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED

     

    By: Janus Capital Management LLC, its investment advisor

	 	 
	 	By:	/s/
Andrew Acker
	 	 	Name:	Andrew
Acker
	 	 	Title:	Authorized Signatory
	 	 	 	 
	 	Address:	151 Detroit Street
	 	 	Denver, CO 80206


 


[Signature Page to Securities Purchase
Agreement]


 






    


     


    

 


	 	PURCHASER:
	 	 
	 	Sphera Biotech Master Fund LP
	 	 
	 	By:	/s/
Michelle Ross
	 	 	Name:	Michelle
Ross
	 	 	Title:	Portfolio Manager & Partner
	 	 	 	 
	 	Address:	PO Box 309, Ugland House, Grand
	 	 	Cayman, KY1-1104, Cayman Islands


 


[Signature Page to Securities Purchase
Agreement]


 






    


     


    

 


	 	PURCHASER:
	 	 
	 	Sphera Global Healthcare Master Fund
	 	 	 
	 	By:	/s/
Michelle Ross
	 	 	Name:	Michelle
Ross
	 	 	Title:	Portfolio Manager & Partner
	 	 
	 	Address:	PO Box 309, Ugland House, Grand
	 	 	Cayman, KY1-1104, Cayman Islands


 


[Signature Page to Securities Purchase
Agreement]


 






    


     


    

 


Schedule A


 


Purchaser Share Amounts


 


	Purchaser	 	Shares

 Purchased	 	 	Purchase Price

 (in $)	 
	Avoro Life Sciences Fund LLC	 	 	3,929,273	 	 	$	39,999,999.14	 
	Invus Public Equities, L.P.	 	 	2,946,955	 	 	$	30,000,001.90	 
	Janus Henderson Biotech Innovation Master Fund Limited	 	 	491,159	 	 	$	4,999,998.62	 
	Sphera Biotech Master Fund LP	 	 	211,198	 	 	$	2,149,996	 
	Sphera Global Healthcare Master Fund	 	 	279,961	 	 	$	2,850,003